This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ibutilide fumarate
Description: Corvert is predominantly a class III antiarrhythmic (see below). Specifically, it blocks the IKr current and activates the INas current. Its primary effect is to prolong the duration of the electrical impulse traversing the heart (action potential) and the time where tissue is refractory to a new impulse. It is available in an IV formulation.
The Vaughan Williams Classification is as follows: I (blocks sodium channel; subclasses based on their effect on action potential duration), II (blocks beta-adrenergic receptors), III (blocks potassium efflux), IV (blocks L-type calcium channels, affecting conduction through the AV node between the upper and lower chambers of the heart), V (other).
Additional information available to subscribers only: